{"name":"Processa Pharmaceuticals","slug":"processa","ticker":"PCSA","exchange":"NASDAQ","domain":"processapharma.com","description":"Processa Pharmaceuticals is a biopharmaceutical company focused on developing innovative treatments for rare diseases. The company's proprietary prodrug platform enables the creation of novel, safer, and more effective medications. With a strong pipeline of promising candidates, Processa Pharmaceuticals is well-positioned to address significant unmet medical needs in the rare disease space.","hq":"Hanover, MD, USA","founded":0,"employees":"","ceo":"David Young","sector":"Rare Disease / Prodrug Platform","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$18M","metrics":{"revenue":5000,"revenueGrowth":-95.6,"grossMargin":0,"rdSpend":5799518,"netIncome":-13563834,"cash":7813567,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2016"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"PCSA-5001 patent cliff ($0.0B at risk)","drug":"PCSA-5001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Processa Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Processa Pharmaceuticals announced its financial results for the fourth quarter and full year 2023, highlighting progress in its pipeline and operational efficiency.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Processa Pharmaceuticals Enters into Licensing Agreement with a Global Pharmaceutical Company","summary":"Processa Pharmaceuticals entered into a licensing agreement with a global pharmaceutical company to develop and commercialize its lead prodrug candidate.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQMDhETS1lVXliVm5ra1RHMGJOdWp5bzh3SGRxUUdzSkp6QmNadTFLYzMxTy1peVZMQ3Q0b2VZLWF5SDQwendMLUU3d2NZRHIxaG1OSjhDbDhUQm96dGpPZFkyUDlfaVhLNmpEZENhSi1XNk82MUNyMndtYkFCdTJnbEhzbk1mVEhTSWpYT1ZNOXJYbmZDZEhqOEl1MkdodXp4b2lLbkE5NlQwYk81eExfSGVzNmNkaDFiNnduZXQ3MA?oc=5","date":"2026-04-01","type":"deal","source":"Stock Titan","summary":"Processa (NASDAQ: PCSA) CDO buys 2,107 shares in open-market trade - Stock Titan","headline":"Processa (NASDAQ: PCSA) CDO buys 2,107 shares in open-market trade","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQUlhpbHNrS1dHZ0xUOUhIcUg2M0lxWjVZSXNQaEZ5T3Uta2ljRlk2Vlg2ZUJVZHdCcmVUNUotWVlZUlU4djR0OGdnRHFfVmdla1hzUTc2b2FDcFdOMVZXVWQ5WndreUtkaGJYZ1QyUnc3ejZLVGdsa2FpUE1tZDVQRFFoOGNaWjZvQVhVSWRiVG90RHlyd1pyZl91NGpybktCMFVVUmQwaEhjczZyRGNnaXR3cXN4azBZb3NQMkpKZTVFNVU?oc=5","date":"2026-04-01","type":"deal","source":"Investing.com","summary":"Processa Pharma chief business officer Lin buys $4063 in PCSA - Investing.com","headline":"Processa Pharma chief business officer Lin buys $4063 in PCSA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQOUk3aVMxTEQxeDR5X3VOSjV6Z2NpNXZMLUE1WFhsZmRCdkNlZTlWZGdXZEZ5bWtlOHpTbVRzOEVPempjUkV4eHp2SEhJZEQ1TzhlY0tISjU3cENBV2JQVHVlRmRNOXAzdlM5dGh3aUlma0NKbEdKY2lsdDVBaUNubDBJaHc4ZzU5Z29qcmYtWm81U0REZ2c0S2FmWUVlWjJZeVZsV2Nvbkh2SGd0SGhfNkFiNFl4RWR6UVNwMF85VWo?oc=5","date":"2026-04-01","type":"deal","source":"Investing.com","summary":"Ng George K, Processa Pharma CEO, buys PCSA stock worth $5414 - Investing.com","headline":"Ng George K, Processa Pharma CEO, buys PCSA stock worth $5414","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOeUJHSHVvaldEbjROMTJZbTVJcWU4S1NNYlQxNWhfRERTWUU1cV9lOGFDdS1NQVZjNUxOR2E5bE1fR2NQcXFLSThEd2FUbkRtdGZqOHIzakNzSF96TS1UN21uT0tsVnJfR0JIYk05c1p1eXVJX3UxNnB6eUFhemc1X015bWctSHhIclRwN3p3V3NwT29jYmlWRzZ6cV9nRk5ONzZFNGE5TS1uRGIyRW96QkxVY3NiXzJLS0Vz?oc=5","date":"2026-04-01","type":"deal","source":"Investing.com","summary":"Processa Pharma director Pannu buys $5,252 in PCSA stock - Investing.com","headline":"Processa Pharma director Pannu buys $5,252 in PCSA stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOWHR3R3dCMU1iRTJCc041QjB5eUdaUTZtRERpZDdQQnYtNnJtYlk1eEdfOXhPV2RyX3BrQ2NQZHFENDU1LWswUlEyMzRMR3VjQ0pUQ0JfM0gwRnNPdDF4aW80Ni1jU1NEMG5RMGdDNlRJMFRNRGY2UnVxaTNnN1RQM29IM1M5RUhJbWV5bnUzaUhHZlV2TnFYSVhJc3lBcjd2Y1N4d2FRWVBydm16SWhkeVdNX1pIOWQyWVFPTjl3SDJXd0JwMFhrdA?oc=5","date":"2026-04-01","type":"deal","source":"Investing.com","summary":"Russell Skibsted, CFO, buys Processa Pharma (PCSA) shares worth $5,891 - Investing.com","headline":"Russell Skibsted, CFO, buys Processa Pharma (PCSA) shares worth $5,891","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOc3l0MWdpb3VoQVpvZnkxalZyVVU1V3VqUnMxaEpDNUphZEpHeXpfSDZheU1tRDBVeWQ4bVRpanplQW51QTR2VHhMeEgxWUNzWDFaUmYyTVBWZTBVNk9ldHVfQUJ4NzcxTFNwSnpUS1R6T0NXQ1l4RW9teWh6N3BoaFRtaXpnOG5vbEp4a1g5Z3lLZVVwdlBFcXgyU0tPcnhrRFJpbnFudFVLZ1dQMHBZMkpIdWg3RFduZTBxaVUybXlBSE0?oc=5","date":"2026-04-01","type":"deal","source":"Investing.com","summary":"Young David, processa pharma pres, buys PCSA shares worth $4588 - Investing.com","headline":"Young David, processa pharma pres, buys PCSA shares worth $4588","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE96LTdmT0Z6ZkZwSzlXTFZqeFk5RDZON1FmQ1BBTDhLblltbVZPRFhIejJTMzRyTkd4VDFNNGQtMjIwUU8zZmVibWZEeVdlbFMxbzRuVzk1N05CbHBiUzFrUE93d1pHYVROYzY4TjFn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Processa Pharmaceuticals Inc (PCSA) - Stock Titan","headline":"If You Invested $1,000 in Processa Pharmaceuticals Inc (PCSA)","sentiment":"neutral"},{"date":"2026-03-18","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQazVGZkxsSEtJRndhQXQ5eWRPYUI3R0Jmcnh3WWdnSEVEdHFkUFNXejV1MHEyOFRKX3NGZ2ExQVlKeUljU0IzWVZUam9XaUdMelprM1lhcm5zWTlkLVhkWXZncXlWLXhHaHhhV21GS2J6d1FGLW14NjQ3VloxLUlaQnN0X01XVXVsbHlrWDQyaEZ6b2xQbFN0TW1FX0NWaDBCbDJ1aXFNbEp4YkhGUkpnclJBckJPN243UWlNQ0VoQkw?oc=5","date":"2026-01-12","type":"trial","source":"Stock Titan","summary":"Breast cancer trial data in focus as Processa joins major health event - Stock Titan","headline":"Breast cancer trial data in focus as Processa joins major health event","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOODFaNGFUMVU3SmZwc0tVbE8zN3Uzdm0tdFhjOXl2ajVBMzRLME5wRlNIWGdNdFMxazVCa1BtTnNsY0hnay1TNm8xZ19LcEQ5TktNODBFLTJHUFJnUGJMNHJUMWRZSlNqYi1razU5N1ZqZ0trcFpDeEVWaklvMGp3a3B4bnRRSlZ0OUF0Nll0UXRLb3poRThjeVB0S1lLNnNBN2xvZ21WM2VlblZSOVJZejdwTmZSWFRIVW1OT2NiZjNPTFNoVTgxSFpNX0xpdk1ldVN5TDdCdHZUbVB1dGx4VUlmZTZMbV9la3dWQw?oc=5","date":"2025-12-18","type":"trial","source":"TechStock²","summary":"Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025 - TechStock²","headline":"Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Wat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOSVVxNHg0eFhTQmYxTDdmdUtqai1lX0xXVVh5NFplYVB1ZEk1ZjVaRlJSbXNwRWM3X0pHclRqZmFaYkdzNFl0TzRYOTg1bjJ4VFZSUUoyS1J6NTAyOUUtanZFckhsOEVWRGtDRWtPMWFEYnh5S2h6Nzk5T2RtSFhpUWZQdnVHWXE1VGNudDkwZGFVSzlnNU9UQTJxRlBod21ndnh4WFhNMFpDdnFxdU81WU9qTllKM1FiajQxa1ktbi1lNVBGTlhOVTlTT0VkZFdoUkhrcVUtWE4tSm1uZ1lRS2UxdmNPNTJxaGpJSzVuX2VpNzZ1MWFkdFp3?oc=5","date":"2025-12-17","type":"trial","source":"GlobeNewswire","summary":"Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer - GlobeNewswire","headline":"Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer","sentiment":"positive"},{"date":"2025-12-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPZmhyMGY3Z3U1TjhRLVl1UjktZzJieU1KRDB0aW10SjRqeFp2RW5xNUVKZFh2YVhIbm8tOHFsUzBsVUtId1JYWmV2VnJOc1RTSUJJSXBreXFmSHI0TVdHQ21fZEVjQ3pnX1V1WWtzNlJmdnpSS3hyMFdWRVdfbG04eGFVQ0NiTll2YndzcUx6V1dwUEczMUg0dXhwQVZtN1I0UWZhRDQyMkFzUlgtVTBTaWgxUDMwUzA?oc=5","date":"2025-10-08","type":"pipeline","source":"Benzinga","summary":"Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight? - Processa Pharma (NASDAQ:PCSA) - Benzinga","headline":"Why Processa Pharmaceuticals Stock Rose Almost 38% Overnight? - Processa Pharma (NASDAQ:PCSA)","sentiment":"neutral"}],"patents":[{"drugName":"PCSA-5001","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biohaven Pharmaceuticals","Catalyst Pharmaceuticals","United Therapeutics"],"therapeuticFocus":["Rare Diseases","Neurological Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":5000,"revenuePeriod":"2016-12-31","revenueHistory":[{"value":5000,"period":"2016-12-31"},{"value":113425,"period":"2015-12-31"},{"value":113425,"period":"2015-12-31"},{"value":200201,"period":"2014-12-31"},{"value":107239,"period":"2014-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":5799518,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-13563834,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":7813567,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}